455 related articles for article (PubMed ID: 17183623)
1. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis.
Mäkinen H; Kautiainen H; Hannonen P; Möttönen T; Leirisalo-Repo M; Laasonen L; Korpela M; Blåfield H; Hakola M; Sokka T
J Rheumatol; 2007 Feb; 34(2):316-21. PubMed ID: 17183623
[TBL] [Abstract][Full Text] [Related]
2. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.
Korpela M; Laasonen L; Hannonen P; Kautiainen H; Leirisalo-Repo M; Hakala M; Paimela L; Blåfield H; Puolakka K; Möttönen T;
Arthritis Rheum; 2004 Jul; 50(7):2072-81. PubMed ID: 15248204
[TBL] [Abstract][Full Text] [Related]
3. Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug.
Kuuliala A; Leirisalo-Repo M; Möttönen T; Hannonen P; Nissilä M; Kautiainen H; Korpela M; Julkunen H; Hakola M; Repo H;
Clin Exp Rheumatol; 2005; 23(2):243-6. PubMed ID: 15895898
[TBL] [Abstract][Full Text] [Related]
4. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
5. Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis.
Laivoranta-Nyman S; Möttönen T; Hannonen P; Korpela M; Kautiainen H; Leirisalo-Repo M; Julkunen H; Luukkainen R; Hakala M; Vuori K; Laine AP; Toivanen A; Ilonen J;
Clin Exp Rheumatol; 2006; 24(6):636-42. PubMed ID: 17207378
[TBL] [Abstract][Full Text] [Related]
6. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.
Aletaha D; Smolen JS
Arthritis Rheum; 2011 Dec; 63(12):3702-11. PubMed ID: 21953215
[TBL] [Abstract][Full Text] [Related]
7. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
[TBL] [Abstract][Full Text] [Related]
9. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
[TBL] [Abstract][Full Text] [Related]
10. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
[TBL] [Abstract][Full Text] [Related]
11. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
[TBL] [Abstract][Full Text] [Related]
12. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
Katayama K; Okubo T; Sato T; Ito H; Fukai R; Baba H
Mod Rheumatol; 2015 Jan; 25(1):50-5. PubMed ID: 24983407
[TBL] [Abstract][Full Text] [Related]
14. Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?
Konijn NPC; van Tuyl LHD; Boers M; den Uyl D; Ter Wee MM; Kerstens P; Voskuyl AE; van Schaardenburg D; Nurmohamed MT; Lems WF
Arthritis Care Res (Hoboken); 2017 Jul; 69(7):989-996. PubMed ID: 27696732
[TBL] [Abstract][Full Text] [Related]
15. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
Wechalekar MD; Lester S; Proudman SM; Cleland LG; Whittle SL; Rischmueller M; Hill CL
Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
[TBL] [Abstract][Full Text] [Related]
16. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort.
Lillegraven S; Prince FH; Shadick NA; Bykerk VP; Lu B; Frits ML; Iannaccone CK; Kvien TK; Haavardsholm EA; Weinblatt ME; Solomon DH
Ann Rheum Dis; 2012 May; 71(5):681-6. PubMed ID: 21994234
[TBL] [Abstract][Full Text] [Related]
17. Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting.
Vázquez I; Graell E; Gratacós J; Cañete JD; Viñas O; Ercilla MG; Gómez A; Hernández MV; Rodríguez-Cros JR; Larrosa M; Sanmartí R
Clin Exp Rheumatol; 2007; 25(2):231-8. PubMed ID: 17543147
[TBL] [Abstract][Full Text] [Related]
18. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.
Rantalaiho V; Kautiainen H; Korpela M; Hannonen P; Kaipiainen-Seppänen O; Möttönen T; Kauppi M; Karjalainen A; Laiho K; Laasonen L; Hakola M; Peltomaa R; Leirisalo-Repo M;
Ann Rheum Dis; 2014 Nov; 73(11):1954-61. PubMed ID: 23908187
[TBL] [Abstract][Full Text] [Related]
19. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.
Dale J; Stirling A; Zhang R; Purves D; Foley J; Sambrook M; Conaghan PG; van der Heijde D; McConnachie A; McInnes IB; Porter D
Ann Rheum Dis; 2016 Jun; 75(6):1043-50. PubMed ID: 27026689
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort.
Khanna D; Oh M; Furst DE; Ranganath V; Gold RH; Sharp JT; Park GS; Keystone EC; Paulus HE;
Arthritis Rheum; 2007 Apr; 57(3):440-7. PubMed ID: 17394230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
